InMode Ltd vs Tempus AI — how do they compare? InMode Ltd trades at $15.16 (market cap $873.13M), while Tempus AI trades at $55.49 (market cap $9.93B). The key difference: Tempus AI is far larger — about 11.4× InMode Ltd's market cap, and InMode Ltd is trading nearer its 52-week high, Tempus AI nearer its low. Which is the better fit depends on your goals.
| INMD | TEM | |
|---|---|---|
Market Cap | $873.13M | $9.93B |
Sector | Technology | Broad Market / Factor |
52-Week High | $16.62 | $103.25 |
52-Week Low | $12.76 | $41.55 |
Enterprise Value | $376.47M | $10.56B |
Signals from Pluang's Aura AI — not financial advice
InMode (INMD) trades at $15.31, up 1.26% with a bullish technical outlook. The stock shows strong profitability with 76.52% gross margins and 20.69% net income margin, though 2026 earnings guidance suggests margin compression. Recent developments include an unsolicited acquisition offer from Steel Partners at $16.75 per share and ongoing shareholder activism. Technical indicators show bullish moving averages with neutral oscillators, while analyst consensus is divided between Buy and Hold ratings.
The investment case balances attractive valuation metrics (P/E 12.55, EV/EBITDA 5.39) against execution risks and shareholder disputes. Near-term catalysts include the Q3 2026 earnings report and potential acquisition developments. Key risks involve competitive pressures in medical aesthetics and ongoing securities investigations that could impact investor confidence.
Tempus AI (TEM) trades at $52.05, up 12.86% in 24 hours, reflecting strong momentum after Q2 2026 earnings beat revenue estimates and raised 2026 sales guidance. The stock is technically bullish with moving averages supporting upside, while fundamentals show revenue growth to $1.4 billion in 2026 but persistent net losses. Recent news highlights expansion through the Personalis acquisition and AI-driven precision medicine advancements.
Outlook: Growth prospects are robust with AI adoption in healthcare and strategic deals, but high valuation ratios and negative profitability pose risks. Analysts are bullish with a $61.57 consensus target, though cash burn and competitive pressures require monitoring for sustained investor confidence.
Trailing returns across standard periods
InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.
Read more on INMD →Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →